Remdesivir News and Research

RSS

Investigation reveals considerable added benefit of remdesivir for moderately ill COVID-19 patients

Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation.

6 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

The use of flavonoids as antiviral agents against SARS-CoV-2

Researchers in Iran have undertaken a comprehensive review of flavonoids and their antiviral potential against SARS-CoV-2.

2 Jul 2021

Stool transplant may be worth exploring as treatment option for COVID-19

It might be worth exploring stool transplant to treat COVID-19 infection, suggest doctors in a letter published online in the journal Gut, after they used the procedure in two patients to prevent the recurrence of another bacterial infection.

2 Jul 2021

Anti-malarial drug shows promise in the battle against COVID-19

In the "war" that the world has been fighting against COVID-19, scientists have been scanning their arsenals of previously used drugs in hopes of finding any that can be used to treat the disease.

1 Jul 2021

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Study suggests vitamin B12 as a SARS-CoV-2 antiviral

Researchers in the UK and Spain have used a novel drug screening approach to identify compounds that could serve as effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

28 Jun 2021

Remdesivir caused dangerously low heart rate in COVID-19 patients

After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.

25 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

A new study, released as a preprint on bioRxiv* server, shows that a combination of the biological interferon-α and the small molecule nafamostat are effective against SARS-CoV-2 infection in vitro, as well as in vivo.

18 Jun 2021

Researchers prepare for next coronavirus pandemic

Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004.

17 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Researchers develop new imaging technique for studying nanoscale coronavirus-host interactions

Lei S. Qi of Stanford University, California, and colleagues published research showing a potential framework to better characterize coronaviruses' biology. While most high-resolution imaging techniques show the life cycle of coronaviruses, identifying viral or host proteins and genomes remains poorly understood. Their results use multi-color super-resolution imaging allows them to study nanoscopic parts of the coronavirus, including RNA.

14 Jun 2021

Eldelumab and Fenofibrate show potential for COVID-19

In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19.

10 Jun 2021